WO2007109733A3 - Diagnostic and prognostic markers and treatment strategies for multiple sclerosis - Google Patents
Diagnostic and prognostic markers and treatment strategies for multiple sclerosis Download PDFInfo
- Publication number
- WO2007109733A3 WO2007109733A3 PCT/US2007/064532 US2007064532W WO2007109733A3 WO 2007109733 A3 WO2007109733 A3 WO 2007109733A3 US 2007064532 W US2007064532 W US 2007064532W WO 2007109733 A3 WO2007109733 A3 WO 2007109733A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- multiple sclerosis
- diagnostic
- treatment strategies
- prognostic markers
- markers
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/81—Protease inhibitors
- C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
- C07K14/8139—Cysteine protease (E.C. 3.4.22) inhibitors, e.g. cystatin
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/285—Demyelinating diseases; Multipel sclerosis
Abstract
Biological markers for multiple sclerosis, and their use in the diagnosis and clinical applications of the disease, are described.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/857,742 US8114619B2 (en) | 2006-03-21 | 2007-09-19 | Methods for diagnosis and optimizing treatment of multiple sclerosis |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US78442506P | 2006-03-21 | 2006-03-21 | |
US60/784,425 | 2006-03-21 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/857,742 Continuation-In-Part US8114619B2 (en) | 2006-03-21 | 2007-09-19 | Methods for diagnosis and optimizing treatment of multiple sclerosis |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2007109733A2 WO2007109733A2 (en) | 2007-09-27 |
WO2007109733A3 true WO2007109733A3 (en) | 2008-01-24 |
Family
ID=38358000
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2007/064532 WO2007109733A2 (en) | 2006-03-21 | 2007-03-21 | Diagnostic and prognostic markers and treatment strategies for multiple sclerosis |
Country Status (2)
Country | Link |
---|---|
US (1) | US8114619B2 (en) |
WO (1) | WO2007109733A2 (en) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101313184B1 (en) * | 2010-06-24 | 2013-09-30 | 한국표준과학연구원 | Disease Marker Detection Kit and the Detection Method of Disease Marker |
KR20140100543A (en) | 2011-11-29 | 2014-08-14 | 뉴로페이지 파마슈티컬즈, 인크. | Use of p3 of bacteriophage as amyloid binding agents |
ES2641373T3 (en) | 2012-10-02 | 2017-11-08 | Proclara Biosciences, Inc. | Use of P3 bacteriophage fusion proteins as amyloid binding agents |
EP3003349B1 (en) | 2013-05-28 | 2018-12-12 | Proclara Biosciences, Inc. | Polypeptides comprising a modified bacteriophage g3p amino acid sequence with reduced immunogenicity |
WO2015055825A1 (en) | 2013-10-18 | 2015-04-23 | Attoquant Diagnostics Gmbh | Method for diagnosis of primary hyperaldosteronism |
AU2015358504A1 (en) | 2014-12-03 | 2017-06-29 | Proclara Biosciences, Inc. | Polypeptides comprising a modified bacteriophage g3p amino acid sequence lacking a glycosylation signal |
JP6691617B2 (en) * | 2016-05-17 | 2020-04-28 | エルディエックス・プログノスティクス・リミテッド・カンパニーLdx Prognostics Limited Co. | Methods and compositions for providing an assessment of preeclampsia |
EP3472622B1 (en) * | 2016-06-17 | 2020-08-05 | Roche Diagnostics GmbH | Circulating angiopoietin-2 (ang-2) for the prediction of recurrence of atrial fibrillation |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NL154598B (en) | 1970-11-10 | 1977-09-15 | Organon Nv | PROCEDURE FOR DETERMINING AND DETERMINING LOW MOLECULAR COMPOUNDS AND PROTEINS THAT CAN SPECIFICALLY BIND THESE COMPOUNDS AND TEST PACKAGING. |
US3817837A (en) | 1971-05-14 | 1974-06-18 | Syva Corp | Enzyme amplification assay |
US3939350A (en) | 1974-04-29 | 1976-02-17 | Board Of Trustees Of The Leland Stanford Junior University | Fluorescent immunoassay employing total reflection for activation |
US3996345A (en) | 1974-08-12 | 1976-12-07 | Syva Company | Fluorescence quenching with immunological pairs in immunoassays |
US4275149A (en) | 1978-11-24 | 1981-06-23 | Syva Company | Macromolecular environment control in specific receptor assays |
US4277437A (en) | 1978-04-05 | 1981-07-07 | Syva Company | Kit for carrying out chemically induced fluorescence immunoassay |
US4366241A (en) | 1980-08-07 | 1982-12-28 | Syva Company | Concentrating zone method in heterogeneous immunoassays |
US4792447A (en) | 1981-07-23 | 1988-12-20 | Board Of Regents, The University Of Texas System | Anti-immunoglobulin toxin conjugates useful in the treatment of B cell tumors |
US4957939A (en) | 1981-07-24 | 1990-09-18 | Schering Aktiengesellschaft | Sterile pharmaceutical compositions of gadolinium chelates useful enhancing NMR imaging |
US4472509A (en) | 1982-06-07 | 1984-09-18 | Gansow Otto A | Metal chelate conjugated monoclonal antibodies |
US4664911A (en) | 1983-06-21 | 1987-05-12 | Board Of Regents, University Of Texas System | Immunotoxin conjugates employing toxin B chain moieties |
US5045451A (en) | 1988-10-26 | 1991-09-03 | Board Of Regents | Methods for screening antibodies for use as immunotoxins |
US5225538A (en) | 1989-02-23 | 1993-07-06 | Genentech, Inc. | Lymphocyte homing receptor/immunoglobulin fusion proteins |
US6406697B1 (en) | 1989-02-23 | 2002-06-18 | Genentech, Inc. | Hybrid immunoglobulins |
EP0481000B1 (en) | 1989-07-06 | 1999-05-12 | The Regents Of The University Of California | Receptors for fibroblast growth factors |
US5767072A (en) | 1989-09-14 | 1998-06-16 | Board Of Regents, The University Of Texas System | Therapeutic compositions comprising a CD4 peptide and methods of treatment of HIV infections |
US5686072A (en) | 1992-06-17 | 1997-11-11 | Board Of Regents, The University Of Texas | Epitope-specific monoclonal antibodies and immunotoxins and uses thereof |
US5578706A (en) | 1993-11-04 | 1996-11-26 | Board Of Regents, The University Of Texas | Methods and compositions concerning homogenous immunotoxin preparations |
US5541087A (en) | 1994-09-14 | 1996-07-30 | Fuji Immunopharmaceuticals Corporation | Expression and export technology of proteins as immunofusins |
US5925351A (en) | 1995-07-21 | 1999-07-20 | Biogen, Inc. | Soluble lymphotoxin-β receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological disease |
AU3224700A (en) | 1999-02-08 | 2000-08-25 | Chiron Corporation | Fibroblast growth factor receptor-immunoglobulin fusion |
-
2007
- 2007-03-21 WO PCT/US2007/064532 patent/WO2007109733A2/en active Application Filing
- 2007-09-19 US US11/857,742 patent/US8114619B2/en not_active Expired - Fee Related
Non-Patent Citations (7)
Title |
---|
BOLLENGIER F: "CYSTATIN C, ALIAS POST-GAMMA-GLOBULIN: A MARKER FOR MULTIPLE SCLEROSIS?", JOURNAL OF CLINICAL CHEMISTRY & CLINICAL BIOCHEMISTRY, BERLIN, DE, vol. 25, no. 9, 1987, pages 589 - 593, XP009003893 * |
CARRETTE O ET AL: "Truncated cystatin C in cerebrospinal fluid: Technical artefact or biological process? (vol 5, pg 3060, 2005)", PROTEOMICS, vol. 5, no. 14, September 2005 (2005-09-01), pages 3822, XP002447759, ISSN: 1615-9853 * |
DEL BOCCIO ET AL: "Cleavage of cystatin C is not associated with multiple sclerosis", 27 September 2006, XP002447772 * |
HANSSON ET AL: "Cystatin C in cerebrospinal fluid and multiple sclerosis", 9 August 2006, XP002447770 * |
IRANI DAVID N ET AL: "Cleavage of cystatin C in the cerebrospinal fluid of patients with multiple sclerosis.", ANNALS OF NEUROLOGY FEB 2006, vol. 59, no. 2, February 2006 (2006-02-01), pages 237 - 247, XP002447758, ISSN: 0364-5134 * |
NAKASHIMA ET AL.: "Alteration of cystatin C in the cerebrospinal fluid of multiple sclerosis", 6 September 2006, XP002447771 * |
NATH AVINDRA ET AL: "Cleavage of cystatin C in CSF is a biomarker of multiple sclerosis", NEUROLOGY, vol. 64, no. 6, Suppl. 1, March 2005 (2005-03-01), & 57TH ANNUAL MEETING OF THE AMERICAN-ACADEMY-OF-NEUROLOGY; MIAMI BEACH, FL, USA; APRIL 09 -19, 2005, pages A417, XP008082712, ISSN: 0028-3878 * |
Also Published As
Publication number | Publication date |
---|---|
US8114619B2 (en) | 2012-02-14 |
US20100137420A1 (en) | 2010-06-03 |
WO2007109733A2 (en) | 2007-09-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2005027733A3 (en) | Biological markers for diagnosing multiple sclerosis | |
WO2007109733A3 (en) | Diagnostic and prognostic markers and treatment strategies for multiple sclerosis | |
WO2007007173A3 (en) | Human anti-madcam antibodies | |
EP1937150A4 (en) | Probe for ultrasound diagnosis and ultrasound diagnostic system using the same | |
EP2535718A3 (en) | Methods for early diagnosis of kidney disease | |
WO2010004590A3 (en) | Genetic variants as markers for use in urinary bladder cancer risk assessment, diagnosis, prognosis and treatment | |
WO2008112903A3 (en) | Genetic alterations on chromosome 16 and methods of use thereof for the diagnosis and treatment of type 1 diabetes | |
PT1922415E (en) | Use of both rd9 and is6110 as nucleic acid targets for the diagnosis of tuberculosis, and provision of multiplex-compliant is6110 and rd9 targets | |
WO2008104271A3 (en) | Imaging probes | |
WO2006019978A3 (en) | Compositions and methods for diagnosis and treatment of epilepsy | |
WO2010033951A3 (en) | Methods for identification and prediction of multiple sclerosis disease and therapy response | |
WO2008103815A3 (en) | Clinical intervention directed diagnostic methods | |
WO2009016231A3 (en) | Compositions and methods for detecting histamine related disorders | |
WO2008003780A3 (en) | Use of proteins of the sdf-1-family for improvement of axonal plasticity or for axonal regeneration following lesions | |
WO2008034621A3 (en) | Nucleotide phosphorylase for the prophylaxis, treatment or diagnosis of acute lung injury (ali) | |
WO2012049228A3 (en) | Marker sequences for multiple sclerosis and the use thereof | |
WO2009007112A3 (en) | Thrombomodulin for increasing reperfusion and preventing blood vessels obstruction | |
WO2006079925A3 (en) | Oligonucleotide probes for the genomic typifying of erythrocyte systems, methods and relative diagnostic kits | |
AU2005907104A0 (en) | Circulatory System Disease Diagnosis and Treatment | |
AU2005903022A0 (en) | Novel methods of diagnosis and treatment of M. tuberculosis infection and reagents therefor I | |
AU2005905420A0 (en) | Diagnosis, prognosis and treatment of neurodegenerative disease V | |
AU2006901699A0 (en) | Diagnosis, prognosis and treatment of neurodegenerative disease I | |
AU2006902607A0 (en) | Methods of diagnosis and treatment of M.tuberculosis infection and reagents therefor XI | |
WO2012067450A3 (en) | Efemp1 gene as a diagnostic marker for prostate cancer | |
AU2006902538A0 (en) | Diagnosis, prognosis and treatment of neurodegenerative disease XXXII |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 07759028 Country of ref document: EP Kind code of ref document: A2 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 07759028 Country of ref document: EP Kind code of ref document: A2 |